子宫内膜癌从组织学到分子分型的发展过程
The Development Process of Endometrial Cancer from Tissue to Molecular Typing
DOI: 10.12677/acm.2024.1441030, PDF,   
作者: 侯筱茹, 马彩玲：新疆医科大学第一附属医院妇科中心，新疆 乌鲁木齐
关键词: 子宫内膜癌；子宫内膜恶性肿瘤；分子分型；Endometrial Carcinoma； Endometrial Malignancy； Molecular Typing
摘要: 子宫内膜癌(Endometrial cancer, EC)又被命名为子宫体癌，是子宫内膜的恶性肿瘤，随着未来发病数的连年上升以及死亡率回升，子宫内膜癌带来的疾病负担不容忽视。随着基因检测的发展，肿瘤的分子特性是疾病精准诊治和判断预后的重要指标物。本文回顾了EC从组织学病理分型到分子分型的发展过程，并从分子分型对预后的判断价值等方面进行综述，以期为EC的临床个体化精准治疗、疗效预测及预后评估提供有价值的信息。但是，分子分型应用于临床尚需继续深入及大量探究。
Abstract: Endometrial cancer (EC), also named as uterine body cancer, is a malignant tumor of the endometrial lining. With the increase in the number of cases and the rise in mortality in the future, the disease burden brought by endometrial cancer cannot be ignored. With the development of genetic detection, the molecular characteristics of tumors are important indicators for accurate diagnosis and treatment of diseases and prognosis. This article reviewed the development of EC from histological and pathological typing to molecular typing, and analyzed the value of molecular typing for prognosis. The expectation can provide valuable information for clinical individualized accurate treatment, therapeutic effect prediction and prognosis evaluation of EC. However, the application of molecular typing in clinical practice still needs to be further explored.
文章引用：侯筱茹, 马彩玲. 子宫内膜癌从组织学到分子分型的发展过程[J]. 临床医学进展, 2024, 14(4): 356-363. https://doi.org/10.12677/acm.2024.1441030

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Lu, K.H. and Broaddus, R.R. (2020) Endometrial Cancer. The New England Journal of Medicine, 383, 2053-2064. [Google Scholar] [CrossRef] 
[3] 赵湘铃, 段朝晖, 张敏, 等. 中国子宫内膜癌疾病负担状况及流行趋势预测[J]. 中国慢性病预防与控制, 2023, 31(8): 568-573.
[4] Bokhman, J.V. (1983) Two Pathogenetic Types of Endometrial Carcinoma. Gynecologic Oncology, 15, 10-17. [Google Scholar] [CrossRef] [PubMed]
[5] 郑文新, 沈丹华, 郭东辉, 等. 妇产科病理学(上卷) [M]. 第2版. 北京: 科学出版社, 2021: 386.
[6] Travaglino, A., Raffone, A., Gencarelli, A., et al. (2020) TCGA Classification of Endometrial Cancer: The Place of Carcinosarcoma. Pathology & Oncology Research, 26, 2067-2073. [Google Scholar] [CrossRef] [PubMed]
[7] Levine, D.A. and the Cancer Genome Atlas Research Network (2013) Integrated Genomic Characterization of Endometrial Carcinoma. Nature, 497, 67-73. [Google Scholar] [CrossRef] [PubMed]
[8] Raffone, A., Travaglino, A., Mascolo, M., Carbone, L., Guida, M., Insabato, L. and Zullo, F. (2019) TCGA Molecular Groups of Endometrial Cancer: Pooled Data about Prognosis. Gynecologic Oncology, 155, 374-383. [Google Scholar] [CrossRef] [PubMed]
[9] Talhouk, A., McConechy, M.K., Leung, S., Li-Chang, H.H., Kwon, J.S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A.N., Huntsman, D.G., Gilks, C.B. and McAlpine, J.N. (2015) A Clinicallyapplicable Molecular-Based Classification for Endometrial Cancers. British Journal of Cancer, 113, 299-310. [Google Scholar] [CrossRef] [PubMed]
[10] McAlpine, J., Leon-Castillo, A. and Bosse, T. (2018) The Rise of a Novel Classificationsystem for Endometrial Carcinoma; Integration of Molecular Subclasses. The Journal of Pathology, 244, 538-549. [Google Scholar] [CrossRef] [PubMed]
[11] 吕加金, 靳双玲, 李玉凡. 子宫内膜癌分子分型的研究进展[J]. 健康研究, 2023, 43(5): 556-559.
[12] Stelloo, E., et al. (2015) Refining Prognosis and Identifying Targetable Pathways for High-Risk Endometrial Cancer; A TransPORTEC Initiative. Modern Pathology, 28, 836-844. [Google Scholar] [CrossRef] [PubMed]
[13] León-Castillo, A., De Boer, S.M., Powell, M.E., Mileshkin, L.R., Mackay, H.J., Leary, A., Nijman, H.W., Singh, N., Pollock, P.M., Bessette, P., Fyles, A., Haie-Meder, C., Smit, V.T.H.B.M., Edmondson, R.J., Putter, H., Kitchener, H.C., Crosbie, E.J., De Bruyn, M., Nout, R.A., Horeweg, N., Creutzberg, C.L., Bosse, T. and TransPORTEC Consortium (2020) Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit from Adjuvant Therapy. Journal of Clinical Oncology, 38, 3388-3397. [Google Scholar] [CrossRef] 
[14] 谢玲玲, 林荣春, 林仲秋. 《2020NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020, 36(4): 333-339.
[15] Abu-Rustum, N.R., Yashar, C.M., Bradley, K., Campos, S.M., Chino, J., Chon, H.S., Chu, C., Cohn, D., Crispens, M.A., Damast, S., Diver, E., Fisher, C.M., Frederick, P., Gaffney, D.K., George, S., Giuntoli, R., Han, E., Howitt, B., Huh, W.K., Lea, J., Mariani, A., Mutch, D., Nekhlyudov, L., Podoll, M., Remmenga, S.W., Reynolds, R.K., Salani, R., Sisodia, R., Soliman, P., Tanner, E., Ueda, S., Urban, R., Wethington, S.L., Wyse, E., Zanotti, K., McMillian, N.R. and Motter, A.D. (2021) NCCNGuidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal of the National Comprehensive Cancer Network, 19, 888-895. [Google Scholar] [CrossRef] [PubMed]
[16] Walsh, C.S., Hacker, K.E., Secord, A.A., et al. (2023) Molecular Testing for Endometrial Cancer: An SGO Clinical Practice Statement. Gynecologic Oncology, 168, 48-55. [Google Scholar] [CrossRef] [PubMed]
[17] 孙丽丽, 刘格丹, 贾楠, 等. 不同分子分型的子宫内膜癌临床病理特征分析[J]. 肿瘤预防与治疗, 2022, 35(5): 435-441.
[18] Concin, N., Creutzberg, C.L., Vergote, I., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. Virchows Archiv, 478, 153-190. [Google Scholar] [CrossRef] [PubMed]
[19] Oaknin, A., Bosse, T.J., Creutzberg, C.L., et al. (2022) Endometrial Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 860-877. [Google Scholar] [CrossRef] [PubMed]
[20] Abu-Rustum, N., Yashar, C., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S.M., Chino, J., Chon, H.S., Chu, C., Crispens, M.A., Damast, S., Fisher, C.M., Frederick, P., Gaffney, D.K., Giuntoli, R., Han, E., Holmes, J., Howitt, B.E., Lea, J., Mariani, A., Mutch, D., Nagel, C., Nekhlyudov, L., Podoll, M., Salani, R., Schorge, J., Siedel, J., Sisodia, R., Soliman, P., Ueda, S., Urban, R., Wethington, S.L., Wyse, E., Zanotti, K., McMillian, N.R. and Aggarwal, S. (2023) Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21, 181-209. [Google Scholar] [CrossRef] [PubMed]
[21] Santoro, A., Angelico, G., Travaglino, A., et al. (2021) New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines. Cancers, 13, Article 2623. [Google Scholar] [CrossRef] [PubMed]
[22] Karpel, H., Slomovitz, B., Coleman, R.L. and Pothuri, B. (2023) Biomarker-Driven Therapy in Endometrial Cancer. International Journal of Gynecologic Cancer, 33, 343-350. [Google Scholar] [CrossRef] [PubMed]
[23] Berek, J.S., Matias-Guiu, X., Creutzberg, C., et al. (2023) FIGO Staging of Endometrial Cancer: 2023. International Journal of Gynecology & Obstetrics, 162, 383-394. [Google Scholar] [CrossRef] [PubMed]
[24] Jamieson, A., Barroilhet, L.M. and McAlpine, J.N. (2022) Molecular Classification in Endometrial Cancer: Opportunities for Precision Oncology in a Changing Landscape. Cancer, 128, 2853-2857. [Google Scholar] [CrossRef] [PubMed]
[25] Abdulfatah, E., Wakeling, E., Sakr, S., et al. (2019) Molecular Classification of Endometrial Carcinoma Applied to Endometrial Biopsy Specimens: Towards Early Personalized Patient Management. Gynecologic Oncology, 154, 467-474. [Google Scholar] [CrossRef] [PubMed]
[26] Zakhour, M., Cohen, J.G., Gibson, A., et al. (2017) Abnormal Mismatch Repair and Other Clinicopathologic Predictors of Poor Response to Progestin Treatment in Young Women with Endometrial Complexatypical Hyperplasia and Well-Differentiated Endometrial Adenocarcinoma: A Consecutive Case Series. BJOG: An International Journal of Obstetrics & Gynaecology, 124, 1576-1583. [Google Scholar] [CrossRef] [PubMed]
[27] Chung, Y.S., Woo, H.Y., Lee, J.Y., et al. (2021) Mismatch Repair Status Influences Response to Fertility-Sparing Treatment of Endometrial Cancer. American Journal of Obstetrics and Gynecology, 224, 370.E1-370.E13. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, Y., Kang, N., Li, L., et al. (2023) Characteristics of Molecular Classification in 52 Endometrial Cancer and Atypical Hyperplasia Patients Receiving Fertility-Sparing Treatment. Gynecology and Obstetrics Clinical Medicine, 3, 38-43. [Google Scholar] [CrossRef] 
[29] Ruiz, M.P., Huang, Y., Hou, J.Y., Tergas, A.I., Burke, W.M., Ananth, C.V., Neugut, A.I., Hershman, D.L. and Wright, J.D. (2017) All-Cause Mortality in Young Women with Endometrial Cancer Receiving Progesterone Therapy. American Journal of Obstetrics and Gynecology, 217, 669.E1-669.E3. [Google Scholar] [CrossRef] [PubMed]
[30] Park, J.Y. and Nam, J.H. (2015) Progestins in the Fertility-Sparing Treatment and Retreatment of Patients with Primary and Recurrent Endometrial Cancer. Oncologist, 20, 270-278. [Google Scholar] [CrossRef] [PubMed]
[31] Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M.R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. International Journal of Gynecologic Cancer, 31, 12-39. [Google Scholar] [CrossRef] [PubMed]
[32] Alkatout, I. (2015) Kommunikative und Ethische Aspekte der Arzt-Patienten-Beziehung in der Extremsituation. Wiener Medizinische Wochenschrift, 165, 491-498. [Google Scholar] [CrossRef] [PubMed]
[33] De Rocco, S., Buca, D., Oronzii, L., Petrillo, M., Fanfani, F., Nappi, L., Liberati, M., D’Antonio, F., Scambia, G., Leombroni, M., et al. (2022) Reproductive and Pregnancy Outcomes of Fertility-Sparing Treatments for Early-Stage Endometrial Cancer or Atypical Hyperplasia: A Systematic Review and Meta-Analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 273, 90-97. [Google Scholar] [CrossRef] [PubMed]
[34] Giampaolino, P., Cafasso, V., Boccia, D., Ascione, M., Mercorio, A., Viciglione, F., Palumbo, M., Serafino, P., Buonfantino, C., De Angelis, M.C., et al. (2022) Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review. BioMed Research International, 2022, Article ID: 4070368. [Google Scholar] [CrossRef] [PubMed]
[35] Lehrer, S. and Rheinstein, P.H. (2021) FBXW7, L1CAM, and TGM2 in Endometrial Cancer. Cancer, 127, 4103-4104.
[36] Emons, G., Steiner, E., Vordermark, D., et al. (2023) Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures. Geburtshilfe Frauenheilkd, 83, 919-962.
[37] Arciuolo, D., Travaglino, A., Raffone, A., et al. (2022) TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 23, Article 11684. [Google Scholar] [CrossRef] [PubMed]
[38] Huvila, J., Pors, J., Thompson, E.F., et al. (2021) Endometrial Carcinoma: Molecular Subtypes, Precursors and the Role of Pathology in Early Diagnosis. The Journal of Pathology, 253, 355-365. [Google Scholar] [CrossRef] [PubMed]
[39] Mutlu, L., Harold, J., Tymon-Rosario, J., et al. (2022) Immune Checkpoint Inhibitors for Recurrent Endometrial Cancer. Expert Review of Anticancer Therapy, 22, 249-258. [Google Scholar] [CrossRef] [PubMed]
[40] Marabelle, A., Le, D.T., Ascierto, P.A., et al. (2020) Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair—Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 38, 1-10.
[41] 易倩琳, 蒋鹏, 朱梦秋, 等. 免疫组化标志物P53定量表达在Ⅰ~Ⅱ期子宫内膜癌中的预后价值[J]. 中国实用妇科与产科杂志, 2023, 39(5): 568-572.
[42] 刘开江. 子宫内膜癌癌症基因组图谱分子分型临床价值: 机遇, 挑战与突破[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1057-1061.
[43] 王东雁, 李晶, 林仲秋. 《子宫内膜癌分子检测: SGO临床实践声明》介绍[J]. 中国实用妇科与产科杂志, 2023, 39(2): 240-245.
[44] 刘格丹, 冯炜炜. 基于子宫内膜癌分子分型决策临床疗[J]. 中国实用妇科与产科杂志, 2022, 38(3): 378-384.
[45] 贾晴晴, 徐臻, 王利君, 等. 淋巴脉管间隙浸润对早期子宫内膜样癌预后的影响[J]. 中国实用妇科与产科杂志, 2022, 38(6): 646-649.

为你推荐